Development of Group B Streptococcal vaccine
NeoStrep is funded by the European Commission FP7 Programme HEALTH
WORK PACKAGE 1
WP1 will perform dose-finding experiments with GBS-NN for studies of antibody levels, isotyping and longevity of antibody response as well as testing of optimal adjuvant-antigen compositions.
Understand the expected dose and dosing regimen in preparation for toxicology and clinical trials as well as to identify the mechanism of action of anti-GBS-NN antibodies.
The specific objectives are: